Application of phyllanthus emblica extract in preparation of composition with hair follicle treatment and nursing effects
By using the uroglycose extract in hair follicles upregulating Gas6 expression, the problem of regulating the growth status of hair follicles stem cells is solved, and the effect of reducing hair removal and promoting hair growth is achieved. It is suitable for hair growth inhibition caused by the stress hormone corticosterone.
Patent Information
- Application Number
- CN202411060911.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art is difficult to effectively regulate the growth state of hair follicle stem cells, especially in the case of hair loss and hair growth inhibition caused by the stress hormone corticosterone.
The use of yogurt extract upregulates Gas6 expression without affecting the viability of hair papillary cells, thereby regulating the growth state of hair follicle stem cells, and preparing compositions with hair follicle therapeutic and nursing effects.
Effectively reduce hair removal and promote hair growth. It is suitable for hair removal and hair growth inhibition caused by the stress hormone corticosterone. It is suitable for hair follicles of hair, beard hair, eyebrows and eyelashes.
Smart Images

Figure CN118924805A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of hair follicle care, and in particular to the use of an extract of Emblica officinalis in preparing a composition having the efficacy of treating and caring for hair follicles. Background Art
[0002] Emblica extract is an active ingredient extracted from the emblica plant, which has extensive medicinal and edible value. It contains a variety of compounds, including tannins, phenolic acids, flavonoids, terpenes, sterols, and vitamin C. It exhibits antioxidant, anti-inflammatory, immunomodulatory, and hair growth-promoting activities. This versatile natural extract has broad application potential in a variety of fields, including food, pharmaceuticals, health supplements, and cosmetics.
[0003] Hair follicle care refers to a series of care measures and product uses aimed at maintaining the health of hair follicles and promoting hair growth, including cleansing the scalp, providing nutrition, regulating oil secretion, reducing inflammation, anti-oxidation, and activating hair follicle cells, etc., to prevent hair loss, improve hair quality and promote hair regeneration.
[0004] Hair follicle care not only involves daily cleaning and nutritional supplements, but also includes an in-depth understanding and application of the biological characteristics of hair follicles. The hair follicle is a sheath-like structure surrounding the hair root, composed of an inner and outer root sheath and a fibrous sheath. It has the function of allowing the hair to absorb nutrients from the body. The hair absorbs nutrients from the body through the hair follicle to support hair growth. Hair follicle stem cells (HFSCs) are adult stem cells present in the hair follicle that have the ability to self-renew and multidirectionally differentiate. Hair follicle stem cells are responsible for the hair growth cycle, including hair regeneration and replacement. Gas6 (Growth arrest-specific protein 6) is a secretory protein of γ-carboxyglutamate that can participate in regulating the quiescence and hair growth cycle of hair follicle stem cells (HFSCs) by binding to the Axl receptor in the TAM receptor family.
[0005] Studies have found that the stress hormone corticosterone affects the expression of Gas6 by acting on dermal papilla cells, thereby regulating the quiescent state of hair follicle stem cells. This provides a possibility to overcome stress-induced hair growth inhibition by regulating Gas6 expression. Summary of the Invention
[0006] This study found that the extract of Phyllanthus emblica can upregulate the expression of Gas6 without affecting the viability of hair papilla cells, thereby affecting the growth state of hair follicle stem cells and playing a role in regulating the health of hair follicles.
[0007] Based on this, one or more embodiments of the present application provide a use of an extract of Emblica officinalis L. in preparing a composition having hair follicle therapeutic efficacy.
[0008] Furthermore, the hair follicle treatment includes at least one of reducing hair loss and promoting hair growth.
[0009] Furthermore, the hair follicle treatment is suitable for at least one of hair loss and hair growth inhibition caused by the stress molecule corticosterone.
[0010] Furthermore, the hair follicles include at least one of the follicles of hair, beard, eyebrows and eyelashes.
[0011] Furthermore, the composition having the efficacy of treating hair follicles is a medicine;
[0012] The drug comprises an active ingredient and a pharmaceutically acceptable carrier and / or excipient;
[0013] The active ingredient includes emblica officinalis extract.
[0014] Furthermore, the emblica fruit extract is the only active ingredient of the medicine.
[0015] Furthermore, the medicine includes an external medicine.
[0016] Furthermore, the dosage form of the drug includes powder, ointment, pill, wine, lozenge, liquid, aerosol or papule.
[0017] Furthermore, the subject of the drug is a mammal.
[0018] One or more embodiments of the present application also provide a use of an extract of Emblica officinalis L. in preparing a composition having hair follicle care efficacy.
[0019] Furthermore, the hair follicle care includes at least one of preventing hair loss and promoting hair growth.
[0020] Furthermore, the hair follicle care is suitable for at least one of hair loss and hair growth inhibition caused by the stress molecule corticosterone.
[0021] Furthermore, the hair follicles include at least one of the follicles of hair, beard, eyebrows and eyelashes.
[0022] Furthermore, the composition having the effect of caring for hair follicles is a cosmetic composition;
[0023] The cosmetic composition comprises an active ingredient and a cosmetically acceptable carrier;
[0024] The active ingredient includes emblica officinalis extract.
[0025] Furthermore, the emblica fruit extract is the only active ingredient of the cosmetic.
[0026] Furthermore, the dosage forms of the cosmetic include solutions, emulsions, creams, ointments, powders, suspensions, oils and soaps.
[0027] Furthermore, the preparation method of the emblica bud extract comprises extracting the emblica bud with an alcohol-water solvent.
[0028] Furthermore, the emblica extract has at least one of the following characteristics:
[0029] (1) 0.15% to 0.35% total polyphenol content;
[0030] (2) ≥100 ppm gallic acid.
[0031] The present application provides the use of emblica extract in the preparation of a composition with hair follicle treatment and care effects. Studies have shown that emblica extract can upregulate Gas6 expression without affecting the viability of hair papilla cells, thereby affecting the growth state of hair follicle stem cells and playing a role in regulating the health of hair follicles. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] In order to more clearly illustrate the specific implementation methods of the present application or the technical solutions in the prior art, the following is a brief introduction to the drawings required for use in the specific implementation methods or the description of the prior art. Obviously, the drawings described below are some implementation methods of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without any creative work.
[0033] Figure 1 This is the statistical result of the effect of different concentrations of corticosterone on the viability of dermal papilla cells in an embodiment of the present application;
[0034] Figure 2 This is the statistical result of the effect of different concentrations of Phyllanthus emblica extract on the viability of dermal papilla cells in an embodiment of the present application;
[0035] Figure 3 The statistical results of the effects of different concentrations of Phyllanthus emblica extract on the expression levels of Gas6, VEGF and TGF according to one embodiment of the present application are shown. DETAILED DESCRIPTION
[0036] Below in conjunction with embodiment and example, further elaborate the application.It should be understood that these examples are only used to illustrate the application and are not used to limit the scope of the application.In addition, it should be understood that after reading the content taught in this application, those skilled in the art can make various changes or modifications to the application, and these equivalent forms also fall within the protection scope of the claims appended hereto.
[0037] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application pertains. The terms used herein in the specification of this application are for the purpose of describing specific embodiments only and are not intended to limit this application.
[0038] the term
[0039] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:
[0040] The term "and / or" as used herein includes any one of two or more related listed items, and also includes any and all combinations of the related listed items, wherein the arbitrary and all combinations include any combination of two related listed items, any more related listed items, or all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in this application, the technical solution undoubtedly includes technical solutions connected by "logical and" and also undoubtedly includes technical solutions connected by "logical or". For example, "A and / or B" includes three parallel solutions: A, B, and A+B.
[0041] In this application, "further", "further", "particularly" and the like are used for descriptive purposes to indicate differences in content, but should not be understood as limiting the scope of protection of this application.
[0042] In this application, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.
[0043] In this application, when referring to a numerical interval (i.e., a numerical range), unless otherwise specified, the optional numerical distribution within the above numerical interval is considered continuous and includes the two numerical endpoints (i.e., the minimum and maximum values) of the numerical range, as well as every numerical value between the two numerical endpoints. Unless otherwise specified, when a numerical interval refers only to integers within the numerical interval, it includes the two endpoint integers of the numerical range, as well as every integer between the two endpoints. In addition, when multiple ranges are provided to describe features or characteristics, these ranges can be combined. In other words, unless otherwise specified, the ranges disclosed herein should be understood to include any and all subranges subsumed therein.
[0044] In this application, weight can be mass units known in the chemical industry, such as μg, mg, g, and kg.
[0045] Gas6 is a vitamin K-dependent protein whose biological function is primarily achieved through interaction with Tyro3, Axl, and Mer in the TAM receptor family. By binding to the Axl receptor of hair follicle stem cells, Gas6 can promote stem cell proliferation, thereby indirectly promoting hair follicle health and hair growth.
[0046] BMPs, or fibroblast growth factors, are a group of multifunctional cell-signaling proteins secreted primarily by fibroblasts and dermal adipocytes. BMP expression increases during the early quiescent phase of hair follicles and decreases during the late quiescent phase, indicating a key role in regulating the hair follicle cycle. Together with upstream signaling factors such as corticosterone, BMPs influence the expression of Gas6, participating in the quiescence and activation of hair follicle stem cells, thereby influencing hair growth and regeneration. Modulating BMP levels or their signaling pathways could potentially intervene in the health of hair follicles and the hair growth cycle.
[0047] VEGF is vascular endothelial growth factor, whose main function is to promote the formation of capillaries. An increase in VEGF content can improve the ability to provide nutrition to hair follicles and indirectly promote the health of hair follicles.
[0048] TGF is transforming growth factor, a type of pleiotropic cytokine that plays an important role in the formation, development and cycle regulation of hair follicles.
[0049] In the present application, a "composition" may be a combination of multiple substances, and further, may be used in combination, or may be a mixture of the combination.
[0050] In this application, "treating" includes treatment and adjuvant therapy. As used herein, "treating" means to alleviate, slow the progression of, attenuate, or maintain an existing disease or condition. "Treatment" also includes curing, preventing the development of, or alleviating to some extent one or more symptoms of a disease or condition.
[0051] As used herein, "drug" includes any agent, compound, composition, or mixture that provides a pharmacological effect in vivo or in vitro, often with a beneficial effect. The scope of the pharmacological effect of a "drug" on hair follicles is not particularly limited and may be systemic or localized. The activity of the "drug" is also not particularly limited and may be an active substance that interacts with other substances or an inert substance that does not interact.
[0052] One or more embodiments of the present application provide a use of an extract of Emblica officinalis L. in preparing a composition having hair follicle therapeutic efficacy.
[0053] In one embodiment, the hair follicle treatment includes at least one of reducing hair loss and promoting hair growth.
[0054] In one embodiment, the hair follicle treatment is adapted to at least one of hair loss and hair growth inhibition caused by the stress molecule corticosterone.
[0055] In one embodiment, the hair follicles include at least one of scalp, beard, eyebrow and eyelash follicles.
[0056] In one embodiment, the composition having the effect of treating hair follicles is a drug;
[0057] The drug comprises an active ingredient and a pharmaceutically acceptable carrier and / or excipient;
[0058] Active ingredients include emblica officinalis extract.
[0059] "Pharmaceutically acceptable" refers to those ligands, materials, compositions, and / or dosage forms that are suitable for administration to a patient within the scope of sound medical judgment and commensurate with a reasonable benefit / risk ratio.
[0060] "Pharmaceutically acceptable excipients" include, but are not limited to, fillers, disintegrants, binders, and lubricants. Fillers include, but are not limited to, anhydrous powdered sugar, lactose, sucrose, starch, microcrystalline cellulose, and maltodextrin. Disintegrants include, but are not limited to, sodium carboxymethyl starch, cross-linked polyvinylpolypyrrolidone, cross-linked sodium carboxymethyl cellulose, ethyl cellulose, methyl cellulose, sodium lauryl sulfate, and polyvinylpyrrolidone. Binders include, but are not limited to, starch slurry, sodium carboxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, and hydroxypropyl methyl cellulose. Lubricants include, but are not limited to, magnesium stearate, talc, polyethylene glycols, and magnesium laurate.
[0061] A "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. As used herein, the language "pharmaceutically acceptable carrier" includes buffers, sterile water for injection, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, that are compatible with drug administration. Each carrier must be "pharmaceutically acceptable" in the sense of being compatible with the other ingredients in the formulation and not harmful to the patient. Suitable examples include, but are not limited to: (1) sugars such as lactose, glucose, and sucrose; (2) starches such as corn starch, potato starch, and substituted or unsubstituted β-cyclodextrins; (3) cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and suppository waxes; (9) oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn starch, and maltose. Rice oil and soybean oil; (10) glycols such as propylene glycol; (11) polyols such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffer; and (21) other nontoxic compatible substances used in pharmaceutical formulations.
[0062] In one embodiment, the extract of Emblica officinalis is the only active ingredient of the drug.
[0063] In one embodiment, the drug comprises a topical medication.
[0064] Topical medications can be administered topically. Pharmaceutical dosage forms for topical administration include ointments, powders, patches, sprays, and the like. These are prepared by mixing the active ingredient under sterile conditions with a pharmaceutically acceptable carrier and any preservatives, buffers, or, if necessary, propellants.
[0065] In one embodiment, the dosage form of the drug includes powder, ointment, pill, wine, tablet, liquid, aerosol or patch.
[0066] In one embodiment, the subject of the drug is a mammal.
[0067] In this application, the term "subject" refers to a patient who uses a drug or a user of a cosmetic.
[0068] In the present application, a "subject" is an animal, preferably a mammal, more preferably a human, and the subject includes but is not limited to consumers of health foods and patients with diseases, disorders and / or symptoms. The subject in the present invention is preferably a mammal. The term "mammal" mainly refers to warm-blooded vertebrate mammals, including but not limited to: cats, dogs, rabbits, bears, foxes, wolves, monkeys, deer, mice (such as rats, mice), pigs, cattle, sheep, horses, humans, etc., preferably primates, more preferably humans. In the present application, a "patient" refers to an animal, preferably a mammal, such as a human, and also such as a rat or mouse. Different subjects may result in different selection ranges of other ingredients in the aforementioned drugs or health foods.
[0069] One or more embodiments of the present application also provide a use of an extract of Emblica officinalis in preparing a composition having hair follicle care efficacy.
[0070] In one embodiment, the hair follicle care includes at least one of preventing hair loss and promoting hair growth.
[0071] In one embodiment, the hair follicle treatment is adapted to at least one of hair loss and hair growth inhibition caused by the stress molecule corticosterone.
[0072] In one embodiment, the hair follicles include at least one of scalp, beard, eyebrow and eyelash follicles.
[0073] In one embodiment, the composition having hair follicle care effect is a cosmetic;
[0074] Cosmetics include active ingredients and cosmetically acceptable carriers;
[0075] Active ingredients include emblica officinalis extract.
[0076] "Cosmetically acceptable carrier" A cosmetically acceptable carrier refers to any vehicle for a cosmetic, drug or pharmaceutical product that is suitable for use in direct, safe contact with human tissue and / or human hair, and may include, for example, any diluents, solvents, carriers, fillers, etc. Such vehicles can take any form known in the art suitable for application to the skin (or hair), and can include water (e.g., deionized water); vegetable oils; mineral oils; esters such as octapalmitate, isopropyl myristate, and isopropyl palmitate; ethers such as dicaprylyl ether and dimethyl isosorbide; alcohols such as ethanol and isopropyl alcohol; fatty alcohols such as cetyl alcohol, cetearyl alcohol, stearyl alcohol, and diphenyl alcohol; isoparaffins such as isooctane, isododecane, and isohexadecane; silicone oils such as cyclomethicone, dimethicone, dimethicone crosspolymer, polysiloxane, and derivatives thereof, preferably organically modified derivatives; hydrocarbon oils such as mineral oil, petrolatum, isododecane, and polyisobutene; polyols such as propylene glycol, glycerin, butylene glycol, pentylene glycol, and hexylene glycol; waxes such as beeswax and vegetable waxes; or any combination or mixture of the foregoing. Based on the teachings herein, one skilled in the art will be able to select appropriate vehicles, and / or select their amounts, such that one or more desired properties of the cosmetic compositions of the present invention are maintained.
[0077] In one embodiment, the extract of Emblica officinalis is the only active ingredient in the cosmetic composition.
[0078] In one embodiment, the dosage form of the cosmetic includes solutions, emulsions, creams, ointments, powders, suspensions, oils and soaps.
[0079] In one embodiment, the preparation method of the emblica bud extract comprises extracting the emblica bud with an alcohol-water solvent.
[0080] Optionally, the extraction solvent can be a medium-to-high polarity solvent composite system such as alcohol or other alcohol-water solvents, and the alcohol can be a monool, a diol, or a polyol, such as ethanol, propylene glycol, glycerol, etc.
[0081] In one embodiment, the extract of Emblica officinalis contains the following ingredients:
[0082] (1) 0.15% to 0.35% total polyphenol content;
[0083] (2) ≥100 ppm gallic acid.
[0084] The embodiments of the present application will be described in detail below with reference to the examples. It should be understood that these examples are intended to illustrate the present application only and are not intended to limit the scope of the present application. The experimental methods for which specific conditions are not specified in the following examples are preferably referred to the guidance provided in the present application, and can also be based on the experimental manuals or conventional conditions in this area, or according to the conditions recommended by the manufacturer, or with reference to experimental methods known in the art.
[0085] In the following specific examples, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument testing accuracy or operational accuracy are allowed.
[0086] In the following specific embodiments, the emblica extract is extracted from an alcohol / water solvent system, and the emblica is produced in China; the standard is referred to PHYLLANTHUS EMBLICA EXTRACT No. 10668 in the International Standard Chinese Name Catalogue of Cosmetic Raw Materials (2010 Edition).
[0087] The cells were sourced from primary human dermal papilla cells (provided by the First Hospital of Hangzhou).
[0088] Example
[0089] 1. Resuscitate cells
[0090] Purchased DP cells were revived and observed for growth. Cell counts were performed after 2 days and the cells were plated onto 96-well and 12-well plates. The 96-well plates were used to measure cell viability and inhibition rates, while the 12-well plates were used to measure Gas6 expression levels. The plates were incubated overnight in a CO2 incubator (37°C, 5% CO2).
[0091] 2. Liquid preparation
[0092] A sample working solution was prepared, consisting of corticosterone (25 μM to 800 μM) and emblica fruit extract (50 μg / mL to 800 μg / mL).
[0093] 3. Grouping
[0094] When the DP cell plating rate reached about 60%, the drugs were divided into groups and administered. Each group had 3 replicate wells.
[0095] 3.1) First, explore the concentration of corticosterone for modeling experiments. Select a corticosterone concentration of 25 μM to 800 μM for the experiment. The experimental conditions are shown in Table 1.
[0096] Table 1
[0097]
[0098] 3.2) The experimental concentration of the emblica extract was then modeled, and a concentration of 50 μM to 800 μM was selected for the experiment. The experimental conditions are shown in Table 2.
[0099] Table 2
[0100]
[0101] In Table 2, 100 μg / ml corresponds to a raw material concentration of 6.8 mg / mL.
[0102] 3.3) After determining the optimal modeling corticosterone concentration of 100 μM, qPCR quantitative detection of Gas6, VEGF, and TGF was performed on emblica fragrans within the safe concentration range of 50 μM to 200 μM. The experimental conditions are shown in Table 3.
[0103] Table 3
[0104]
[0105] Some experimental groups were pretreated with Phyllanthus emblica extract for 2 hours. After pretreatment, the culture medium was replaced with 100 μM corticosterone supplemented with the extract. After administration, the 96-well and 12-well plates were placed in an incubator (37°C, 5% CO2) and incubated for 72 hours.
[0106] 4. Data processing
[0107] 1) Cell viability test
[0108] 10 μL of CCK-8 reagent was added to each well of a 96-well plate and incubated in an incubator (37° C., 5% CO 2 ) for 3 hours. The absorbance at 450 nm was then measured using a microplate reader.
[0109] 2) Calculation of cell survival rate and inhibition rate
[0110] Cell survival rate (%) = [(As-Ab) / (Ac-Ab)] × 100%;
[0111] Inhibition rate (%) = [(Ac-As) / (Ac-Ab)] × 100%;
[0112] As: absorbance of experimental wells (containing cells, culture medium, CCK-8 solution, and drug solution);
[0113] Ac: absorbance of control well (containing cells, culture medium, and CCK-8 solution, but no drug);
[0114] Ab: absorbance of blank wells (containing culture medium and CCK-8 solution, but not cells or drugs).
[0115] 3) Collect samples
[0116] After the incubation of the 12-well plate, the cells were collected for subsequent testing.
[0117] 4) Gene expression detection
[0118] RNA was extracted, reverse transcribed into cDNA, and quantitative PCR was performed.-△△Ct Method to calculate the results.
[0119] 5. Statistical analysis of results
[0120] Graphs were generated using GraphPad Prism, and the results are expressed as mean ± SD. Comparisons between groups were analyzed using one-way ANOVA. P < 0.05 was considered a significant difference, and P < 0.01 was considered a highly significant difference.
[0121] Figure 1 This is the statistical result of the effect of different concentrations of corticosterone on the viability of dermal papilla cells in an embodiment of the present application. The horizontal axis is the control and different concentrations of corticosterone groups (25μM, 50μM, 100μM, 200μM, 400μM, 800μM) from left to right, and the vertical axis is the cell survival rate (%); according to Figure 1 It can be seen that within the concentration range of 25 μM to 100 μM, the viability of dermal papilla cells is higher than 70%, and the toxicity is relatively low, so it is considered that the next step of the experiment can be carried out.
[0122] Figure 2 This is the statistical result of the effect of different concentrations of Phyllanthus emblica extract on the viability of hair papilla cells in an embodiment of the present application. The horizontal axis from left to right is the control, different concentrations of Phyllanthus emblica extract group (50μM, 100μM, 200μM, 400μM, 800μM), and the vertical axis is the cell survival rate (%); according to Figure 2 It can be seen that within the concentration range of 50μM to 100μM, the viability of dermal papilla cells is higher than 70%, and the toxicity is relatively low. The cell survival rate at a concentration of 200μM is 64.29%, which is used as an auxiliary concentration for quantitative detection of expression levels.
[0123] Figure 3 The statistical results of the effects of different concentrations of emblica extract on the expression levels of Gas6, VEGF and TGF in one embodiment of the present application are shown in Figure 1. The horizontal axis of each small figure is from left to right the control, different concentrations of emblica extract group (50 μM, 100 μM, 200 μM), corticosterone group (100 μM), different concentrations of emblica extract + corticosterone group (50 μM + 100 μM, 100 μM + 100 μM, 100 μM + 200 μM), and the vertical axis is the fold change of the expression level; according to Figure 3 It can be seen that:
[0124] 1) Compared with the blank control group, 100 μM corticosterone significantly reduced the expression level of GAS6 to 72.8%; non-significantly reduced the expression level of VEGF to 91.8%; and significantly reduced the expression level of TGF to 68.9%.
[0125] 2) The extract of Phyllanthus emblica itself can increase the expression levels of three markers: 100 μM can significantly increase the level of GAS6 to 173.9%, 200 μM can significantly increase the level of VEGF to 163.2%, and 200 μM can non-significantly increase the level of TGF to 126.6%.
[0126] 3) Phyllanthus emblica extract can regulate the reduction of marker levels caused by corticosterone:
[0127] 3.1) 50 μM and 100 μM of Phyllanthus emblica extract significantly upregulated the GAS6 reduction induced by 100 μM corticosterone by 134.6% and 183.5%, respectively, while 200 μM had no effect;
[0128] 3.2) 50 μM, 100 μM and 200 μM of Phyllanthus emblica extract significantly upregulated the VEGF reduction induced by 100 μM corticosterone to 147%, 146.5% and 246.9%, respectively;
[0129] 3.3) 50 μM, 100 μM, and 200 μM of Phyllanthus emblica extract significantly upregulated the GAS6 decrease induced by 100 μM corticosterone by 125.3%, 133.9%, and 121.3%, respectively.
[0130] All documents mentioned in this application are cited as references in this application, just as each document is cited as a reference separately. Unless they conflict with the application purpose and / or technical solution of this application, the cited documents involved in this application are cited in their entirety and for all purposes. When cited documents are involved in this application, the definitions of relevant technical features, terms, nouns, phrases, etc. in the cited documents are also cited. When cited documents are involved in this application, the examples and preferred embodiments of the cited relevant technical features may also be incorporated into this application as references, but are limited to the ability to implement this application. It should be understood that when the cited content conflicts with the description in this application, the present application shall prevail or be adaptively amended according to the description in this application.
[0131] The various technical features of the above-mentioned implementation modes and examples can be combined in any appropriate manner. In order to make the description concise, not all possible combinations of the various technical features in the above-mentioned implementation modes and examples are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of the description in this specification.
[0132] The embodiments described above only express several implementation methods of the present application, but they should not be understood as limiting the scope of the patent application. It should be pointed out that, for those of ordinary skill in the art, without departing from the concept of the present application, several variations and improvements can be made, which all fall within the scope of protection of the present application. In addition, it should be understood that after reading the above-mentioned teaching content of the present application, those skilled in the art can make various changes or modifications to the present application, and the equivalent forms obtained also fall within the scope of protection of the present application. It should also be understood that the technical solutions obtained by those skilled in the art through logical analysis, reasoning or limited experiments on the basis of the technical solutions provided in the present application are all within the scope of protection of the claims attached to the present application. Therefore, the scope of protection of the patent application of the present application shall be based on the attached claims, and the description can be used to interpret the content of the claims.
Claims
1. Use of an extract of Emblica officinalis in preparing a composition having hair follicle treatment efficacy.
2. The use according to claim 1, characterized in that: The hair follicle treatment includes at least one of reducing hair loss and promoting hair growth.
3. The use according to claim 2, characterized in that: The hair follicle treatment is suitable for at least one of hair removal and hair growth inhibition caused by the stress molecule corticosterone.
4. The use according to claim 1, characterized in that: The hair follicles include at least one of the follicles of head hair, beard hair, eyebrow hair and eyelash hair.
5. The use according to any one of claims 1 to 4, characterized in that: The composition having the effect of treating hair follicles is a medicine; The drug comprises an active ingredient and a pharmaceutically acceptable carrier and / or excipient; The active ingredient includes emblica extract.
6. The use according to claim 5, characterized in that: The emblica extract is the only active ingredient of the medicine.
7. The use according to claim 5, characterized in that: The medicines include medicines for external use.
8. The use according to claim 7, characterized in that: The dosage form of the drug includes powder, ointment, pill, wine, lozenge, water, aerosol or papule.
9. The use according to claim 5, characterized in that: The subject of the drug is a mammal.
10. Use of an extract of Emblica officinalis in preparing a composition having hair follicle care efficacy.
11. The use according to claim 10, characterized in that: The hair follicle care includes at least one of preventing hair loss and promoting hair growth.
12. The use according to claim 11, characterized in that: The hair follicle care is suitable for at least one of hair loss and hair growth inhibition caused by the stress molecule corticosterone.
13. The use according to claim 10, characterized in that: The hair follicles include at least one of the follicles of head hair, beard hair, eyebrow hair and eyelash hair.
14. The use according to any one of claims 10 to 13, characterized in that: The composition having the effect of hair follicle care is a cosmetic; The cosmetic comprises an active ingredient and a cosmetically acceptable carrier; The active ingredient includes emblica fruit extract.
15. The use according to claim 14, characterized in that: The emblica fruit extract is the only effective ingredient of the cosmetic.
16. The use according to claim 14, characterized in that The dosage forms of the cosmetic include solutions, emulsions, creams, ointments, powders, suspensions, oils and soaps.
17. The use according to any one of claims 1 to 4, 6 to 13 and 15 to 16, characterized in that: The preparation method of the emblica buddha extract comprises extracting the emblica buddha with an alcohol-water solvent.
18. The use according to any one of claims 1 to 4, 6 to 13 and 15 to 16, characterized in that: The emblica extract has at least one of the following characteristics: (1) 0.15% to 0.35% total polyphenol content; (2) ≥100 ppm gallic acid.
Citation Information
Patent Citations
Bathing cream containing emblic leafflower fruit
CN1203076A
